DR info

臨床試験数 : 28 / 薬物数 : 20 - (DrugBank : 9) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 16

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

68Ga-DOTA-TATE PET/MR and PET/CT imaging
   Wuhan Union Hospital, China
      2019   -   NCT04045834   China;
Alfacalcidol
   Haukeland University Hospital
      2009   -   NCT01057186   Norway;
BGJ398
   National Institute of Dental and Craniofacial Research (NIDCR)
      2019   Phase 2   NCT03510455   United States;
Burosumab
   Kyowa Kirin Co., Ltd.
      2018   Phase 3   JPRN-JapicCTI-205284   Japan, Asia except Japan;
      2017   Phase 3   JPRN-JapicCTI-173614   Japan;
      2015   Phase 2   JPRN-JapicCTI-163191   Japan, Asia except Japan;
   Redwood Dermatology Sciences
      2018   Phase 3   NCT03581591   United States;
   Ultragenyx Pharmaceutical Inc
      2018   -   NCT03775187   -
      2015   Phase 2   NCT02304367   United States;
Cinacalcet
   Children's Mercy Hospital Kansas City
      2009   -   NCT00844740   United States;
      2005   Phase 1   NCT00195936   United States;
Combination Product: 68Ga-DOTATATE PET/CT
   Mayo Clinic
      2019   Phase 1/Phase 2   NCT03736564   United States;
Crysvita (burosumab-twza) Treatment
   University of Alabama at Birmingham
      2020   Phase 4   NCT04320316   United States;
High cheese intake.
   University of Aarhus
      2015   -   NCT03348644   Denmark;
High milk intake.
   University of Aarhus
      2015   -   NCT03348644   Denmark;
Iron
   Indiana University
      2014   -   NCT02233322   United States;
KRN23
   Kyowa Hakko Kirin Co., Ltd
      2014   Phase 1   NCT02181764   Japan;Korea, Republic of;
   Kyowa Kirin Co., Ltd.
      2021   Phase 4   NCT04842032   China;
      2021   Phase 4   NCT04842019   China;
      2018   Phase 3   NCT04308096   Japan;Korea, Republic of;
      2018   Phase 3   JPRN-JapicCTI-205284   Japan, Asia except Japan;
      2017   Phase 3   NCT03233126   Japan;
      2017   Phase 3   JPRN-JapicCTI-173614   Japan;
      2016   Phase 2   NCT02722798   Japan;Korea, Republic of;
      2015   Phase 2   JPRN-JapicCTI-163191   Japan, Asia except Japan;
Norditropine simplex
   Bicetre Hospital
      2006   Phase 1/Phase 2   NCT02720770   -
Osteoblast biology study
   Hospices Civils de Lyon
      2020   -   NCT04159675   France;
Osteomalacia
   National Institute of Dental and Craniofacial Research (NIDCR)
      2012   Phase 1   NCT01748812   United States;
Paricalcitol
   Yale University
      2007   Phase 3   NCT00417612   United States;
Phosphate
   The Second Xiangya Hospital, Central South University
      2006   -   ChiCTR-OOC-16010095   China;
Phosphate tablets.
   University of Aarhus
      2015   -   NCT03348644   Denmark;
Phosphate.
   Haukeland University Hospital
      2009   -   NCT01057186   Norway;
Phosphorus
   The Second Xiangya Hospital, Central South University
      2006   -   ChiCTR-OOC-16010095   China;
Sevelamer
   Haukeland University Hospital
      2009   -   NCT01057186   Norway;
Somatropin
   University of Rostock
      2004   Phase 1   NCT00473187   Germany;
Z-521
   Zeria Pharmaceutical
      2010   Phase 3   NCT01237288   Japan;
   Zeria Pharmaceutical Co., Ltd.
      2010   Phase 3   JPRN-JapicCTI-101332   -